View Older Stories View More Recent Stories

Oct 26, 2022 06:00PM Ligand to Report Third Quarter Financial Results on November 7
Oct 26, 2022 08:01AM Ligand Pharma (LGND) Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Oct 26, 2022 08:00AM Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Oct 24, 2022 05:04PM OmniAb Business Combination Approved by APAC Shareholders (AHPA)
Oct 24, 2022 05:00PM OmniAb Business Combination Approved by APAC Shareholders
Oct 3, 2022 04:30PM Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2022 09:00AM Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Aug 24, 2022 05:01PM Ligand Pharma (LGND) Announces that Janssen has Received Approval from EC for TECVAYLI
Aug 24, 2022 05:00PM Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Aug 8, 2022 04:01PM Ligand Reports Second Quarter 2022 Financial Results
Aug 1, 2022 07:22PM Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 22, 2022 04:08PM Ligand to Report Second Quarter Financial Results on August 8
Jun 29, 2022 04:01PM Ligand Pharma (LGND) Appoints Jason Haas to its Board
Jun 29, 2022 04:01PM Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
May 4, 2022 04:01PM Ligand Reports First Quarter 2022 Financial Results
Apr 19, 2022 04:01PM Ligand to Report First Quarter Financial Results on May 4
Apr 8, 2022 04:50PM Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 17, 2022 04:01PM Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 9, 2022 09:01AM Ligand to Report Fourth Quarter Financial Results on February 17
Dec 22, 2021 08:05AM Ligand Pharma (LGND) Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab for First-Line Treatment of Advanced NSCLC in Combination with Chemotherapy
Dec 22, 2021 08:00AM Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Dec 21, 2021 04:02PM Ligand Pharma (LGND), GSK (GSK) Expand Global Collaboration and License Agreement
Dec 21, 2021 04:01PM Ligand and GSK Expand Global Collaboration and License Agreement
Nov 9, 2021 04:02PM Ligand Reports Third Quarter 2021 Financial Results
Nov 9, 2021 04:01PM Ligand Pharma (LGND) Pursuing Plans for OmniAb to Become a Standalone Public Company
Nov 9, 2021 04:01PM Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
Oct 26, 2021 04:01PM Ligand to Report Third Quarter Financial Results on November 9, 2021
Oct 21, 2021 09:00AM Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Aug 30, 2021 04:02PM Ligand Pharma (LGND) Partner Gloria Biosciences Receives Approval in China for Zimberelimab
Aug 30, 2021 04:01PM Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Aug 16, 2021 02:55PM Ligand Pharma (LGND) Partner Travere (TVTX) Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Aug 16, 2021 02:53PM Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Jul 29, 2021 04:01PM Ligand Reports Second Quarter 2021 Financial Results
Jul 21, 2021 09:00AM Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Jul 19, 2021 08:12AM Ligand's (LGND) Partner Merck (MRK) Receives FDA Approval for VAXNEUVANCE for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Jul 19, 2021 08:00AM Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Jul 16, 2021 09:00AM Ligand to Report Second Quarter Financial Results on July 29, 2021
Jul 14, 2021 04:01PM Ligand Pharma (LGND) Appoints Jennifer Cochran to its Board
Jul 14, 2021 04:01PM Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
May 3, 2021 04:01PM Ligand Reports First Quarter 2021 Financial Results
Apr 22, 2021 04:01PM Ligand to Report First Quarter Financial Results on May 3, 2021
Feb 3, 2021 07:30AM Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 2, 2021 11:59AM Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Jan 20, 2021 08:30AM Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
Jan 13, 2021 08:33AM Ligand Pharma (LGND) Receives Milestone Payment from Merck
Jan 13, 2021 08:30AM Ligand Receives Milestone Payment from Merck
Dec 21, 2020 08:32AM Ligand Pharma (LGND), GSK (GSK) Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Dec 21, 2020 08:30AM Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Nov 23, 2020 08:30AM Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
Nov 6, 2020 02:17PM Ligand Pharma's (LGND) Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT for Treatment of Status Epilepticus in Adult and Pediatric Patients
View More Recent Stories View Older Stories